IW Capital has launched their innovative new EIS Portfolio Service, allowing access to investment into the UK’s wealth of high-growth SMEs through the EIS. The service will cater to both advisers and private investors with a simple transparent fee structure providing investors the ability to claim tax relief on the full investment amount.

Launched after considerable demand from IFAs, the service will allow easier routes to investment in a fast-growing sector of the UK economy for clients looking to diversify their portfolios with high-growth private companies.

Deepbridge Capital, the tax-efficient investment manager and Enterprise Investment Scheme (EIS) provider, has announced the exit of its holding in iPipeline Holdings Inc., with iPipeline being acquired by Florida tech-holding firm, Roper Technologies, for $1.63 billion.

With many fund managers already fundraising and more expected to join them, it has never been more important to understand the market. At this year's VCT & EIS Investor Forum delegates including private investors, financial advisers and wealth managers, will have an unirivalled opportunity to hear from some of the UK's most successful VCT and EIS  fund managers on the issues that matter to the industry. 

Hardman & Co has published its latest report, The Truth About What Lies Beneath, has been written to coincide with the launch of the Hardman & Co panel and research services for Business Relief (BR) products.

Community interest company ‘Community Mentoring and Support’ (CMAS) is the latest social enterprise to receive investment of £250,000 from the Resonance Bristol Social Investment Tax Relief (SITR) Fund, managed by social impact investment company Resonance.

Crowd2Fund has been formally granted their Advanced Assurance from HMRC for the Enterprise Investment Scheme (EIS) tax relief. This means that now up to £12,000,000 can be invested into the growth of Crowd2Fund under the scheme, from private investors or specialist EIS funds. It is a tremendously generous scheme, through which investors receive excellent tax incentives for investing in businesses, like Crowd2Fund, who offer benefits to the wider economy.

EIS Fund Manager Par Equity has realised its 17th company exit with the sale of the market-leading videogame data analysis firm, deltaDNA.  The terms of the acquisition are commercially confidential, but Par investors will receive a return of many multiples of their original investment.  This follows on from Par Equity’s exit from ICS Learn last year, which rewarded investors with a return of 76x money, before any tax benefits. 

Deepbridge Capital investee company Afin Technologies (formerly SurveyMe), has acquired Entertainment - the Michigan-based promotional discounts company.

The deal will see the creation of a business fully focused on the North American couponing market providing new investment to what is seen as a traditional American pastime.

Deepbridge Capital has to date provided over £7m of funding to Afin Technologies via its Deepbridge Technology Growth Enterprise Investment Scheme (EIS) fund.

Symvan Capital, an EIS fund manager, has announced that B.heard, a pioneer in the monetisation of the European personal data economy, has been purchased by Sweetbridge Inc., an American company at the forefront of the blockchain economy.  

Hardman & Co is leading a new initiative to support (S)EIS funds entering the investment market. It has brought together a wide range of professional services providers with the specific aim of advising, educating and supporting new funds at the start of their journey. By understanding at the outset all the elements needed for a successful launch, the new entrant is in a better position to come to market faster and in a more co-ordinated way.

Echopoint Medical Ltd, a spinout company from UCL, has raised £2.8m to develop optical sensing technology to help heart disease patients in a grey zone where the need for treatment is unclear.

Coronary heart disease is a major cause of death worldwide and more than 7 million* people have a diagnosis in the UK alone. Narrowing arteries caused by the disease are commonly treated by the insertion of tiny tubes called stents, but the process is both risky and expensive.

The EISA's Summer 2019 edition of Zeitgeist discusses the tricky question of risk and what it really means in relation to EIS investments.